GNE-149

• Description :

  GNE-149 is an orally bioavailable full antagonist of estrogen receptor α (ERα; IC50=0.053 nM) . GNE-149 is a selective estrogen receptor degrader (SERD) . GNE-149 can be used for the research of breast cancer[1].

• UNSPSC :

  12352005

• Target :

  Estrogen Receptor/ERR

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/gne-149.html

• Concentration :

  10mM

• Purity :

  99.18

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CC(C)(F)CN1[C@@](C2=C(C=C(C=C2F)OC3CN(C3)CCCF)F)([H])C4=C(C[C@H]1C)C5=CC=CC=C5N4

• Molecular Formula :

  C28H33F4N3O

• Molecular Weight :

  503.57

• References & Citations :

  [1]Jun Liang, et al. Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer. ACS Med Chem Lett. 2020 May 26;11 (6) :1342-1347.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  ERα

• CAS Number :

  [1953132-75-6]